Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology

Gómez-Rial, José; Currás-Tuala, María José; Rivero‐Calle, Irene; Gómez-Carballa, Alberto; Cebey-López, Miriam; Rodrı́guez-Tenreiro, Carmen; Dacosta-Urbieta, Ana; Rivero-Velasco, Carmen; Rodríguez-Núñez, Nuria; Peña, Rocı́o; Rodrı́guez-Garcı́a, Javier; Salas, Antonio; Martinón-Torres, Federico

doi:10.3389/fimmu.2020.560381

Cited by 66 publications

(60 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding is in line with a recent report by Gómez-Rial et al. that showed higher sCD163 and sCD14 plasmatic levels in patients with COVID-19 pneumonia compared to controls ( 43 ). In our study, after stratifying COVID-19 subjects according to the development of ARDS, we observed higher baseline sCD163 and sCD14 plasmatic levels in the ARDS compared to the non-ARDS group.…”

Section: Discussionsupporting

confidence: 93%

“…Moreover, high sCD14 plasmatic levels were reported in patients with ARDS, bacterial pneumonia and diffuse interstitial lung diseases ( 16 ). Data regarding sCD163 and sCD14 plasmatic levels in patients with COVID-19 pneumonia are still limited, and their potential use as prognostic markers is under investigation in a few reports from the scientific literature ( 43 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia

et al. 2021

View full text Add to dashboard Cite

BackgroundEmerging evidence argues that monocytes, circulating innate immune cells, are principal players in COVID-19 pneumonia. The study aimed to investigate the role of soluble (s)CD163 and sCD14 plasmatic levels in predicting disease severity and characterize peripheral blood monocytes and dendritic cells (DCs), in patients with COVID-19 pneumonia (COVID-19 subjects).MethodsOn admission, in COVID-19 subjects sCD163 and sCD14 plasmatic levels, and peripheral blood monocyte and DC subsets were compared to healthy donors (HDs). According to clinical outcome, COVID-19 subjects were divided into ARDS and non-ARDS groups.ResultsCompared to HDs, COVID-19 subjects showed higher sCD163 (p<0.0001) and sCD14 (p<0.0001) plasmatic levels. We observed higher sCD163 plasmatic levels in the ARDS group compared to the non-ARDS one (p=0.002). The cut-off for sCD163 plasmatic level greater than 2032 ng/ml was predictive of disease severity (AUC: 0.6786, p=0.0022; sensitivity 56.7% [CI: 44.1–68.4] specificity 73.8% [CI: 58.9–84.7]). Positive correlation between plasmatic levels of sCD163, LDH and IL-6 and between plasmatic levels of sCD14, D-dimer and ferritin were found. Compared to HDs, COVID-19 subjects showed lower percentages of non-classical (p=0.0012) and intermediate monocytes (p=0.0447), slanDCs (p<0.0001), myeloid DCs (mDCs, p<0.0001), and plasmacytoid DCs (pDCs, p=0.0014). Compared to the non-ARDS group, the ARDS group showed lower percentages of non-classical monocytes (p=0.0006), mDCs (p=0.0346), and pDCs (p=0.0492).ConclusionsThe increase in sCD163 and sCD14 plasmatic levels, observed on hospital admission in COVID-19 subjects, especially in those who developed ARDS, and the correlations of these monocyte/macrophage activation markers with typical inflammatory markers of COVID-19 pneumonia, underline their potential use to assess the risk of progression of the disease. In an early stage of the disease, the assessment of sCD163 plasmatic levels could have clinical utility in predicting the severity of COVID-19 pneumonia.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia

et al. 2021

View full text Add to dashboard Cite

show abstract

“…These data underlined the presence of strong activation of the monocytic lineage on hospital admission due to SARS-CoV-2 infection in conjunct with LPS translocation and inflammatory exacerbation in ICU patients (28). In according with this study, systemic markers of monocyte activation, mainly sCD14 and sCD163, correlated with inflammatory cytokines in a non-intensive care unit COVID-19 cohort patients (29).…”

Section: Discussionsupporting

confidence: 75%

Increased LPS levels coexist with systemic inflammation and result in monocyte activation in severe COVID-19 patients

Teixeira

Dorneles

Filho

et al. 2021

Preprint

View full text Add to dashboard Cite

This study aimed to evaluate the link between microbial translocation markers and systemic inflammation at the earliest time-point after hospitalization and at the last 72 h of hospitalization in survivors and non-survivors COVID-19 patients. Sixty-six SARS-CoV-2 RT-PCR+ infected patients and nine non-COVID-19 pneumonia controls were admitted in this study. Blood samples were collected at hospital admission (T1) (Controls and COVID-19+ patients) and 0-72 h before hospital discharge (T2, alive or dead) to analyze systemic cytokines and chemokines, LPS concentrations, and soluble CD14 (sCD14) levels. THP-1 human monocytic cell line was incubated with plasma from survivors and non-survivors COVID-19 patients and their phenotype, activation status, TLR4, and chemokine receptors were analyzed by flow cytometry. COVID-19 patients presented higher IL-6, IFN-γ, TNF-α, TGF-β1, CCL2/MCP-1, CCL4/MIP-1β, and CCL5/RANTES levels than controls. Moreover, LPS and sCD14 were higher at hospital admission in SARS-CoV-2-infected patients. Non-survivors COVID-19 patients had increased LPS levels concomitant with higher IL-6, TNF-α, CCL2/MCP-1, and CCL5/RANTES levels at T2. Increased expression of CD16 and CCR5 were identified in THP-1 cells incubated with the plasma of survivor patients obtained at T2. The incubation of THP-1 with T2 plasma of non-survivors COVID-19 leads to higher TLR4, CCR2, CCR5, CCR7, and CD69 expression. In conclusion, increased microbial translocation during hospitalization coexist with the inflammatory condition of SARS-CoV-2 infection and could lead to higher monocyte activation in non-survivors COVID-19 patients.

show abstract

“…Soluble CD163 is considered a marker of monocyte/macrophage activation, and high levels of soluble CD163 have been linked to several pathologic conditions, such as infectious disease or autoimmunity ( Ingels et al, 2013 ). Accordingly, sCD163 is increased in plasma of SARS-CoV-2–infected individuals and has been associated with the progression to severe COVID-19 ( Gómez-Rial et al, 2020 ; Zingaropoli et al, 2021 ). Although IVIG-treated COVID-19 patients showed an improvement on their clinical status that was associated with a decreasing trend in several biomarkers related to innate cells activation and recruitment, the levels of sCD163 showed a rapid increasing tendency (as early as 3 d after the first administration of IVIG) ( Fig 1C ).…”

Section: Resultsmentioning

confidence: 99%

High-dose intravenous immunoglobulins might modulate inflammation in COVID-19 patients

et al. 2021

View full text Add to dashboard Cite

The use of high-dose of intravenous immunoglobulins (IVIGs) as immunomodulators for the treatment of COVID-19–affected individuals has shown promising results. IVIG reduced inflammation in these patients, who progressively restored respiratory function. However, little is known about how they may modulate immune responses in COVID-19 individuals. Here, we have analyzed the levels of 41 inflammatory biomarkers in plasma samples obtained at day 0 (pretreatment initiation), 3, 7, and 14 from five hospitalized COVID-19 patients treated with a 5-d course of 400 mg/kg/d of IVIG. The plasmatic levels of several cytokines (Tumor Necrosis Factor, IL-10, IL-5, and IL-7), chemokines (macrophage inflammatory protein-1α), growth/tissue repairing factors (hepatic growth factor), complement activation (C5a), and intestinal damage such as Fatty acid–binding protein 2 and LPS-binding protein showed a progressive decreasing trend during the next 2 wk after treatment initiation. This trend was not observed in IVIG-untreated COVID-19 patients. Thus, the administration of high-dose IVIG to hospitalized COVID-19 patients may improve their clinical evolution by modulating their hyperinflammatory and immunosuppressive status.

show abstract

Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology

Abstract: F (2020) Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology.

Cited by 66 publications

References 27 publications

Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia

Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia

Increased LPS levels coexist with systemic inflammation and result in monocyte activation in severe COVID-19 patients

High-dose intravenous immunoglobulins might modulate inflammation in COVID-19 patients

Contact Info

Product

Resources

About